Answers are grounded in this paper and cite their sources.
The emergence of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has re-established TB as a major worldwide health concern [1–3]. Compared with conventional TB drug regimens, treatments for MDR-TB and XDR-TB are more toxic, expensive and associated with poorer outcomes [3, 4]. In Germany, 102 (2.4%) of the 4318 TB cases reported for 2013 were MDR-TB, including 10 patients with XDR-TB [5], increasing from 54 (1.8%) cases in 2011 [5, 6]. An important factor behind the increase in Germany is migration, with more cases occurring in patients from the former Soviet Union than in native Germans [5]. Adding bedaquiline to the background regimen is likely to be cost-effective for treatment of MDR/XDR-TB in Germany <http://ow.ly/SwMdv>
No takes yet. Share an insight, caveat, or question.
Wolfson et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: